Press release
January 12, 2026
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
CRISPR Therapeutics AG (CRSP)
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY ® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases-